Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by ForexWhaleon May 04, 2019 12:43pm
104 Views
Post# 29710793

RE:RE:Can't believe is under 10

RE:RE:Can't believe is under 10I think this stock got lot of people screwed up with that spike to 26 cents last year. people just thought its going to go higher and higher but it was definitely a spike only. shorters made lot of money and thats about it.

Since then management is also kind of silent and no positive news came out. We have few things that can happen in favor of the company like ICO-019 phase 2 start, IC0-008 licensing, any other drug candidate, clinical board hiring etc. But I think lesson to be learnt is that biopharma is not for every one. Its a patience game and for a long time your money can be stuck in a losing position. But this wont stay in this range forever. Outlook is positive but timing is not. So if you are in it for quick buck , then think of somewhere else. this aint the stock.
<< Previous
Bullboard Posts
Next >>